<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338815</url>
  </required_header>
  <id_info>
    <org_study_id>5784</org_study_id>
    <nct_id>NCT04338815</nct_id>
  </id_info>
  <brief_title>Exoskeleton Variability Optimization</brief_title>
  <official_title>Exoskeleton Variability Optimization for Reducing Gait Variability for Patients With Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska, Omaha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska, Omaha</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate a potentially faster and more clinically feasible method to
      optimize exoskeletons in pilot tests in healthy in preparation for patients with peripheral
      artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to convergence</measure>
    <time_frame>10 minutes</time_frame>
    <description>We will determine when the estimated optimal exoskeleton settings vary less than 10%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak extension timing</measure>
    <time_frame>20 seconds</time_frame>
    <description>Timing of peak extension moment of exoskeleton (% stride cycle)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak flexion timing</measure>
    <time_frame>20 seconds</time_frame>
    <description>Timing of peak flexion moment of exoskeleton (% stride cycle)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Largest Lyupunov exponent</measure>
    <time_frame>20 seconds</time_frame>
    <description>Largest Lyapunov exponent of lower limb kinematics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Determine optimal assistance pattern</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Determine effects on endurance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exoskeleton optimization</intervention_name>
    <description>Participants will walk 10 times 1 minute while an optimization algorithm changes the assistance profile of an exoskeleton.</description>
    <arm_group_label>Determine optimal assistance pattern</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endurance evaluation</intervention_name>
    <description>Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.</description>
    <arm_group_label>Determine effects on endurance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written consent

          -  Chronic claudication history

          -  Ankle-brachial index &lt; 0.90 at rest

          -  Stable blood pressure, lipides, and diabetes for &gt; 6 weeks

          -  Ability to walk on a treadmill for multiple five-minute spans.

          -  Ability to fit in exoskeleton: waist circumference 78 to 92 centimeters, thigh
             circumference 48 to 60 centimeters, minimal thigh length 28 centimeters.

        Exclusion Criteria:

          -  Rest pain or tissue loss due to PAD (Fontaine stage III and IV).

          -  Foot ulceration.

          -  Acute lower extremity event secondary to thromboembolic disease or acute trauma

          -  Walking capacity limited by diseases which are unrelated to PAD such as:

        Neurological disorders, musculoskeletal disorders (arthritis, scoliosis, stroke, spinal
        injury, etc.), a history of ankle instability, knee injury, diagnosed joint laxity, lower
        limb injury, surgery within the past 12 months, joint replacement, pulmonary disease or
        breathing disorders, cardiovascular disease, or vestibular disorder. This will be
        determined by verbal questioning from research personnel by verbally asking about
        conditions limiting their walking, whether subjects are taking medications for those
        conditions, and physicians' recommendations about limiting activity.

          -  Acute injury or pain in their lower extremity or current illness.

          -  Inability to follow visual cues due to blindness.

          -  Inability to follow auditory cues due to deafness.

          -  Women who are currently pregnant are excluded for safety reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Malcolm</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska, Omaha</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Malcolm, PhD.</last_name>
    <phone>6174871148</phone>
    <email>pmalcolm@unomaha.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska, Omaha</investigator_affiliation>
    <investigator_full_name>Philippe Malcolm</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Exoskeleton</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

